RxDoctor Payments Data

Elizabeth Rudolphi

Medical · Albuquerque, NMNPI 1922425735

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $436, more than ten times the $30 reported in 2021.

$1,156in general payments, 2019–2025

Across 63 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$243
  • Lilly USA, LLC$157
  • Astellas Pharma US Inc$132
  • Amgen$99
  • Otsuka America Pharmaceutical, Inc.$66
  • Exact Sciences$63
  • plus $397 from 12 others

What the payments were for

  • Food & beverage$1,156100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,156 in reported general payments places this provider in the 75th percentile of 156 medical providers in New Mexico.

See all medical providers in New Mexico

Medicare billing

Part B allowed, 2024
$16,945
Medicare patients
179
Services billed
263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron11$5,566
Fluticasone Propionate27$1,436
Atorvastatin Calcium55$999
Estradiol12$748
Pantoprazole Sodium19$620
Gabapentin60$597
Levothyroxine Sodium45$513
Albuterol Sulfate HfaAlbuterol Sulfate18$478
Losartan Potassium28$404
Amlodipine Besylate29$371
Lisinopril37$370
Tamsulosin Hcl14$370
Omeprazole23$355
Irbesartan14$344
Diclofenac Sodium15$343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$132$5,56611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 156 medical providers in New Mexico.

Other medical in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →